Diligence memo · auto-generated · as of July 2, 2026

Bioscale Inc

Bioscale Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Bioscale Inc operates in Biotechnology, based in LEXINGTON.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Bioscale Inc has raised $45M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $19M on 2013-06-21.

Most recent recorded round closed around 2013-06-21.

Valuation (modeled)modeled

Provath models Bioscale Inc at approximately $748M (range $38M–$2.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.05× the median modeled value of Series B Biotechnology companies in 2013–2015 (77 peers) — value vs value, same stage and era. Within the normal band (105% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 9 months.

Last raise 13.0 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 17.7× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 80% of Biotechnology peers (4293 compared).

Modeled value ranks above 86% of those peers.

Closest niche peers: BioAtla,LLC, Scholar Rock LLC, Oligasis, LLC, Alector LLC, Gelesis Inc.

Peoplefiled

23 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.